OTCPK:MKEA.F

Stock Analysis Report

Executive Summary

Mauna Kea Technologies SA, a medical device company, designs, develops, and markets endomicroscopy and optical biopsy tools for the diagnosis and treatment of gastrointestinal cancers and other diseases worldwide.

Snowflake

Fundamentals

High growth potential with imperfect balance sheet.

Risks

  • Mauna Kea Technologies is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Mauna Kea Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:MKEA.F

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

n/a

OTCPK:MKEA.F

8.7%

US Medical Equipment

1.7%

US Market

No trading data on MKEA.F.

No trading data on MKEA.F.


Share holder returns

MKEA.FIndustryMarket
7 Day0%-1.2%1.2%
30 Day0%1.4%4.9%
90 Dayn/a4.8%3.7%
1 Yearn/a9.6%8.7%3.9%1.7%
3 Year-62.9%-62.9%70.8%65.5%47.2%37.7%
5 Year-77.6%-77.6%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Mauna Kea Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mauna Kea Technologies undervalued based on future cash flows and its price relative to the stock market?

4.89x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Mauna Kea Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Mauna Kea Technologies to establish if it is available at substantial discount.


Price Based on Earnings

Mauna Kea Technologies is loss making, we can't compare its value to the US Medical Equipment industry average.

Mauna Kea Technologies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Mauna Kea Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

Mauna Kea Technologies is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Mauna Kea Technologies expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

43.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Mauna Kea Technologies's revenue is expected to grow significantly at over 20% yearly.

Mauna Kea Technologies's earnings are expected to grow significantly at over 20% yearly.

Mauna Kea Technologies's revenue growth is expected to exceed the United States of America market average.

Mauna Kea Technologies's earnings growth is expected to exceed the United States of America market average.

Mauna Kea Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Mauna Kea Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Mauna Kea Technologies performed over the past 5 years?

3.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Mauna Kea Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Mauna Kea Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Mauna Kea Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Mauna Kea Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Mauna Kea Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Mauna Kea Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Mauna Kea Technologies's financial position?


Financial Position Analysis

Mauna Kea Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Mauna Kea Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Mauna Kea Technologies's level of debt (88.4%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (11% vs 88.4% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Mauna Kea Technologies has less than a year of cash runway based on current free cash flow.

Mauna Kea Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.3% each year.


Next Steps

Dividend

What is Mauna Kea Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Mauna Kea Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Mauna Kea Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Mauna Kea Technologies has not reported any payouts.

Unable to verify if Mauna Kea Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Mauna Kea Technologies has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Mauna Kea Technologies's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Mauna Kea Technologies's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Rob Gershon (52yo)

0.9yrs

Tenure

€825,498

Compensation

Mr. Robert L. Gershon, also known as Rob, has been Chief Executive Officer and Director at Mauna Kea Technologies SA since October 22, 2018. He served as the Chief Executive Officer of Bovie Medical Corpor ...


CEO Compensation Analysis

Rob's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Rob to compare compensation growth.


Management Age and Tenure

2.0yrs

Average Tenure

The tenure for the Mauna Kea Technologies management team is about average.


Board Age and Tenure

2.1yrs

Average Tenure

52yo

Average Age

The average tenure for the Mauna Kea Technologies board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • John Soto (55yo)

    Chief Operating Officer

    • Tenure: 2.6yrs
  • Sacha Loiseau

    Co-Founder & Chairman

    • Tenure: 0.9yrs
    • Compensation: €1.26m
  • François Lacombe

    Chief Scientific Officer

    • Tenure: 0yrs
  • Bruno Villaret

    Global Director of Sales

    • Tenure: 0yrs
  • Christophe Lamboeuf

    CFO & Deputy CEO

    • Tenure: 1.4yrs
  • Rob Gershon (52yo)

    CEO & Director

    • Tenure: 0.9yrs
    • Compensation: €825.50k

Board Members

  • Joe Devivo (52yo)

    Independent & Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: €42.78k
  • Sacha Loiseau

    Co-Founder & Chairman

    • Tenure: 0.9yrs
    • Compensation: €1.26m
  • Molly O'Neill (55yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: €33.56k
  • Chris McFadden

    Independent Director

    • Tenure: 11.7yrs
  • Rob Gershon (52yo)

    CEO & Director

    • Tenure: 0.9yrs
    • Compensation: €825.50k
  • Jennifer Tseng

    Independent Director

    • Tenure: 2.5yrs

Company Information

Mauna Kea Technologies SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mauna Kea Technologies SA
  • Ticker: MKEA.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €39.052m
  • Listing Market Cap: €43.247m
  • Shares outstanding: 25.16m
  • Website: https://www.maunakeatech.com

Number of Employees


Location

  • Mauna Kea Technologies SA
  • 9, rue d'Enghien
  • Paris
  • Ile-de-France
  • 75010
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MKEAENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2011
0P5ILSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2011
MKEAPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2011
MKEA.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2011
1MKDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2011

Biography

Mauna Kea Technologies SA, a medical device company, designs, develops, and markets endomicroscopy and optical biopsy tools for the diagnosis and treatment of gastrointestinal cancers and other diseases wo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:12
End of Day Share Price2019/08/06 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.